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Purpose
In 2009, the Childhood Arthritis and Rheumatology
Research Alliance (CARRA) established a longitudinal
multi-center, multiple disease U.S. national registry (CAR-
RAnet) for pediatric rheumatology with the intent of pro-
viding 60 participating clinical sites a new framework to
drive observational clinical research and evidence-based
care. CARRAnet seeks to enroll up to 20,000 subjects with
childhood-onset rheumatic disease and twice yearly fol-
low-up. We report baseline characteristics of the initial
6-month enrollment cohort; disease-specific results are
reported separately.
Methods
Enrollment commenced 5/29/2010 with data available
through 12/28/10. Inclusion criteria comprised 1 of 8 cate-
gories of defined rheumatic disease with onset before the
16th birthday in subjects <=21 years (localized sclero-
derma, juvenile dermatomyositis, juvenile idiopathic
arthritis, juvenile primary fibromyalgia syndrome, SLE or
mixed connective tissue disease, sarcoidosis, systemic
sclerosis, and vasculitis). A common baseline data set and
1 disease-specific data set was completed on each partici-
pant by interview and chart review. Data cleaning and ana-
lysis employed Microsoft Excel and Access (Microsoft
Corp), SAS (SAS Institute), and R (R Foundation for
Statistical Computing).
Results
1638 subjects were enrolled from 27 centers throughout
the US. The analysis cohort reflected 1371 subjects,
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Table 1 Summary characteristics of CARRAnet initial
cohort
Demographic measures N (%)
Total participants studied 1371
Female gender 1024 (75%)
White/caucasian 1187 (87%)
Age at onset of symptoms, mean in years 7.2
Age at baseline visit, mean in years 11.8
Black or African American 127 (9%)
Asian 45 (3%)
American Indian or Alaska Native 30 (2%)
Native Hawaiian or Pacific Islander 9 (<1%)
Hispanic ethnicity 150 (11%)
Primary rheuamtic diagnosis
Juveline idiopathic arthritis 1051 (77%)
Juveline dematophyositis 109 (8%)
Systemic lupus erythematosus 100 (7%)
Localized scleroderma 43 (3%)
Mixed connective tissue disease 23 (2%)
Vasculitis 23 (2%)
Systemic sclerosis 9 (<1%)
Sarcoidosis 8 (<1%)
Juveline primary fibromyalgia syndrome 6 (<1%)
Growth parameters Mean & (Range)
Weight Z-score 0.28 (-5.3 – 4.7)
Height Z-score -0.14 (-19.7 – 9.4)
BMI Z-score 0.38 (-5.0 – 4.1)
Assessments (scale: best -> worst) Mean & (Range)
Physician global assess disease activity (0 – 10) 1.6 (0 – 10)
Subject global assess disease activity (0 – 10) 2.3 (0 – 10)
Subject pain score (0 – 10) 2.4 (0 – 10)
CHAQ (0 – 3) 0.33 (0 – 3)
HRQOL – Good, very good, excellent (%) 96%
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predominantly JIA; 63 variables were collected for the
shared baseline form with summary statistics presented
in the figures. The population reported overall good to
excellent health by patient and physician report: 96%
with mean HRQOL good to excellent; physician mean
global assessment of disease activity (PGAS) 1.6 (0-10
scale). PGAS correlated with subject reports (CHAQ,
subject global, subject pain scores – Pearson corr 0.33,
0.39, 0.42 respectively). Medication use was prevalent,
including 74% ever on steroids, 41% ever on biologics,
and 31% currently on biologics. Growth was within nor-
mal on average, but exhibited wide deviation
(-5.3>weight Z > 4.7, -19.7>height Z>9.4). A similarly
wide range was seen on both objective and subjective
measures, identifying probable subpopulations with high
disease activities.
Conclusion
The initial CARRAnet cohort reflects predominantly low
disease activity with favorable self-reports. This is not a
population study and issues of enrollment bias require
further investigation. Despite the overall well-being of
the population, the high use of steroids, biologics, and
DMARDs, along with significant subpopulations con-
cerning for high disease activity, are important areas of
future focus.
Table 1 Summary characteristics of CARRAnet initial
cohort (Continued)
HRQOL – Very poor, poor (%) 3%
Family history (first degree relative) of N (%)
Psoriasis 82 (6%)
Rheumatoid arthritis 71 (5%)
Autoimmune throiditis 62 (5%)
Fibromyalgia 61 (4%)
Juvenile idiopathic arthritis 55 (4%)
Diabetes type I 35 (3%)
Inflammatory bowel disease 31 (2%)
Systemic lupus erthematosus 28 (2%)
Spondyloarthritis or ankyl. spondylitis 16 (1%)
Multiple sclerosis 13 (1%)
Celiac disease 10 (1%)
Uveitis 5 (<1%)
Medication use N (%)
Steroids (ever) 1010 (74%)
Steroids (longterm daily, ever) 644 (47%)
Steroids (IV pulse, ever) 212 (15%)
Steroids (IA, ever) 529 (39%)
Biologics (ever) 560 (41%)
Biologics (current) 429 (31%)
TNF-a Blockers (current) 338 (25%)
DMARDs (ever) 1107 (81%)
DMARDs (current) 1021 (75%)
Methotrexate (current) 620 (45%)
NSAIDs (current) 625 (46%)
Opioids (current) 17 (1%)
Figure 1 Disease onset distributions
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